Identification of whole blood gene expressions correlated with responsiveness to benralizumab - 04/02/21
Doi : 10.1016/j.jaci.2020.08.004
Masayuki Nakajima, MD, PhD a, Masashi Matsuyama, MD, PhD a 
, Naoki Arai, MD b, Hideyasu Yamada, MD, PhD c, d, Kentaro Hyodo, MD b, Mizu Nonaka, MD b, Haruna Kitazawa, MD a, Kazufumi Yoshida, MD a, Rie Shigemasa, MD a, Yuko Morishima, MD, PhD a, Takumi Kiwamoto, MD, PhD a, Hironori Masuko, MD, PhD a, Yukio Ishii, MD, PhD a, Masafumi Muratani, PhD e, Takefumi Saito, MD, PhD b, Nobuyuki Hizawa, MD, PhD a
, Naoki Arai, MD b, Hideyasu Yamada, MD, PhD c, d, Kentaro Hyodo, MD b, Mizu Nonaka, MD b, Haruna Kitazawa, MD a, Kazufumi Yoshida, MD a, Rie Shigemasa, MD a, Yuko Morishima, MD, PhD a, Takumi Kiwamoto, MD, PhD a, Hironori Masuko, MD, PhD a, Yukio Ishii, MD, PhD a, Masafumi Muratani, PhD e, Takefumi Saito, MD, PhD b, Nobuyuki Hizawa, MD, PhD a a Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
b National Hospital Organization Ibarakihigashi National Hospital, Naka-gun, Ibaraki, Japan
c Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
d Division of Respiratory Medicine, Hitachi Hitachinaka General Hospital, Tsukuba, Ibaraki, Japan
e Department of Genome Biology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| This study was supported by a Grant-in-Aid for Scientific Research B (19H03663) from the Japan Society for the Promotion of Science and Clinical Research Support Program from the Japanese Society of Allergology. |
|
| Disclosure of potential conflict of interest: N. Hizawa is on the GlaxoSmithKline advisory board; has received research support from Astellas, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kyorin, MSD, Novartis, and Chugai Pharmaceutical; and has received lecture fees from Astellas, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kyorin, MSD, and Novartis. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 147 - N° 2
P. 772-775 - février 2021 Retour au numéro
Article précédent
- A model-based approach for assessing bronchodilator responsiveness in children: The conventional cutoff revisited
- Gianluca Sottile, Giuliana Ferrante, Giovanna Cilluffo, Salvatore Fasola, Velia Malizia, Vito M.R. Muggeo, Giovanni Viegi, Stefania La Grutta
- Human immune disorder associated with homozygous hypomorphic mutation affecting MALT1B splice variant
- Necil Kutukculer, Thomas Seeholzer, Thomas J. O’Neill, Carina Graß, Ayca Aykut, Neslihan Edeer Karaca, Asude Durmaz, Ozgur Cogulu, Guzide Aksu, Torben Gehring, Andreas Gewies, Daniel Krappmann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?